Search results for "primary Sjogren's syndrome"

showing 3 items of 3 documents

The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus

2021

International audience; Autoimmune diseases (AIDs) share similar serological, clinical, and radiological findings, but, behind these common features, there are different pathogenic mechanisms, immune cells dysfunctions, and targeted organs. In this context, multiple lines of evidence suggest the application of precision medicine principles to AIDs to reduce the treatment failure. Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient, thus it could be a new approach for management of AIDS which considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would also assist physicians in ch…

0301 basic medicinerheumatoid arthritismedicine.medical_specialtyantiphospholipid syndrome; precision medicine; primary sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosis; consensus; humans; precision medicine; autoimmune diseases; lupus erythematosus systemic; sjogren's syndromeConsensusspondyloarthritidesystemic sclerosisImmunologysystemic lupus erythematosuSjogren's Syndrome.Context (language use)Consensuprimary Sjogren's syndromeAutoimmune DiseaseTreatment failureAutoimmune DiseasesNOEfficacy03 medical and health sciences0302 clinical medicineprimary Sjogren’s syndromeAcquired immunodeficiency syndrome (AIDS)systemic lupus erythematosusmedicineImmunology and AllergyHumansLupus Erythematosus SystemicIn patientIntensive care medicineAdverse effect030203 arthritis & rheumatologybusiness.industryPrecision medicinePrecision medicine; antiphospholipid syndrome; primary Sjogren’s syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisEnvironmental exposurerheumatoid arthritimedicine.diseasePrecision medicineantiphospholipid syndrome; Precision medicine; primary Sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisspondyloarthritides3. Good health030104 developmental biologySjogren's Syndrome[SDV.IMM]Life Sciences [q-bio]/Immunologybusinesssystemic sclerosiantiphospholipid syndromeHuman
researchProduct

A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndrome

2020

Abstract Objectives This phase 2 proof-of-concept study (NCT02610543) assessed efficacy, safety and effects on salivary gland inflammation of seletalisib, a potent and selective PI3Kδ inhibitor, in patients with moderate-to-severe primary Sjögren’s syndrome (PSS). Methods Adults with PSS were randomized 1:1 to seletalisib 45 mg/day or placebo, in addition to current PSS therapy. Primary end points were safety and tolerability and change from baseline in EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) score at week 12. Secondary end points included change from baseline at week 12 in EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) score and histological features in salivary …

Male0301 basic medicineSalivamedicine.medical_specialtyPyridinesprimary Sjögren’s syndromeAdministration Oralprimary Sjogren's syndromePlaceboProof of Concept StudyGastroenterologySalivary Glandshistologyseletalisib03 medical and health sciences0302 clinical medicineDouble-Blind MethodRheumatologyInternal medicineproof-of-conceptmedicineHumansPharmacology (medical)Adverse effect030203 arthritis & rheumatologySalivary glandbiologySurrogate endpointbusiness.industryMiddle Agedmedicine.diseaseSialadenitisphosphatidylinositol 3-kinase delta (PI3K delta)primary Sjögren's syndrome3. Good healthSjogren's Syndrome030104 developmental biologymedicine.anatomical_structureTolerabilityImmunoglobulin MAntirheumatic Agentsphosphatidylinositol 3-kinase delta (PI3Kδ)Quinolinesbiology.protein[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemalebusiness
researchProduct

Compromised central tolerance of ICA69 induces multiple organ autoimmunity

2014

For reasons not fully understood, patients with an organ-specific autoimmune disease have increased risks of developing autoimmune responses against other organs/tissues. We identified ICA69, a known β-cell autoantigen in Type 1 diabetes, as a potential common target in multi-organ autoimmunity. NOD mice immunized with ICA69 polypeptides exhibited exacerbated inflammation not only in the islets, but also in the salivary glands. To further investigate ICA69 autoimmunity, two genetically modified mouse lines were generated to modulate thymic ICA69 expression: the heterozygous ICA69(del/wt) line and the thymic medullary epithelial cell-specific deletion Aire-ΔICA69 line. Suboptimal central neg…

Primary Sjogren's syndromeGenetically modified mouseImmunologyThyroid GlandAutoimmune diabeteMice TransgenicThymus GlandBiologymedicine.disease_causeAutoantigensArticleSalivary GlandsSettore MED/13 - EndocrinologiaAutoimmune DiseasesAutoimmunityImmune toleranceAutoimmune thyroiditisIslets of LangerhansMiceICA69Mice Inbred NODImmune TolerancemedicineAnimalsImmunology and AllergyThymuAutoimmune thyroiditiNOD miceInflammationAutoimmune diseaseStomachmedicine.diseaseGene Expression RegulationAutoimmune polyendocrine syndromeImmunologyAutoimmune polyendocrine syndromeCentral toleranceJournal of Autoimmunity
researchProduct